Efficacy of probiotics in pediatric atopic dermatitis: A systematic review and meta-analysis

IF 4.6 2区医学 Q2 ALLERGY Clinical and Translational Allergy Pub Date : 2023-07-15 DOI:10.1002/clt2.12283

Xiali Xue, Xinwei Yang, Xiubo Shi, Zhongyi Deng

{"title":"Efficacy of probiotics in pediatric atopic dermatitis: A systematic review and meta-analysis","authors":"Xiali Xue, Xinwei Yang, Xiubo Shi, Zhongyi Deng","doi":"10.1002/clt2.12283","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Atopic dermatitis (AD) is a prevailing skin disease in childhood. Several studies have appraised probiotics as a strategy for treating AD. We aimed to assess the validity of probiotics in the treatment of AD in children.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We systematically searched the PubMed/MEDLINE, Embase, Scopus, EBSCO, Web of Science and Cochrane library databases for randomized controlled trials (RCTs) that assessed the effect of probiotic treatment on SCORAD value in pediatric patients with AD compared with a placebo group between 1 January 2010 and 1 January 2023. The risk of bias and the certainty of evidence were assessed using Cochrane ROB 2.0.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 10 outcomes from 9 RCTs involving 1000 patients were included. Three of these outcomes were analyzed as dichotomous variables in 373 patients. The other seven were analyzed for continuous variables in 627 patients. A meta-analysis of the random-effect model of the dichotomous variables demonstrated no significant difference between the probiotic and control groups [OR = 1.75, 95% confidence interval (CI) (0.70, 4.35), <i>p</i> = 0.23, <i>I</i><sup>2</sup> = 68%]. A meta-analysis of the random-effect model of continuous variables demonstrated significant differences between the probiotic and control groups [MD = −4.24, 95% CI (−7.78, −0.71), <i>p</i> = 0.002, <i>I</i><sup>2</sup> = 71%]. Subgroup analysis of continuous variables showed that the effects of children's age, treatment duration and probiotic species on the SCORAD value were not statistically significant.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Evidence on the improvement effect of probiotics on pediatric patients with AD is limited. This study showed that single-strain probiotic treatment exerts a positive effect on AD. Restricted to the quantity and quality of incorporated studies, these conclusions have yet to be validated by high-quality studies.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12283","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12283","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background

Atopic dermatitis (AD) is a prevailing skin disease in childhood. Several studies have appraised probiotics as a strategy for treating AD. We aimed to assess the validity of probiotics in the treatment of AD in children.

Methods

We systematically searched the PubMed/MEDLINE, Embase, Scopus, EBSCO, Web of Science and Cochrane library databases for randomized controlled trials (RCTs) that assessed the effect of probiotic treatment on SCORAD value in pediatric patients with AD compared with a placebo group between 1 January 2010 and 1 January 2023. The risk of bias and the certainty of evidence were assessed using Cochrane ROB 2.0.

Results

A total of 10 outcomes from 9 RCTs involving 1000 patients were included. Three of these outcomes were analyzed as dichotomous variables in 373 patients. The other seven were analyzed for continuous variables in 627 patients. A meta-analysis of the random-effect model of the dichotomous variables demonstrated no significant difference between the probiotic and control groups [OR = 1.75, 95% confidence interval (CI) (0.70, 4.35), p = 0.23, I² = 68%]. A meta-analysis of the random-effect model of continuous variables demonstrated significant differences between the probiotic and control groups [MD = −4.24, 95% CI (−7.78, −0.71), p = 0.002, I² = 71%]. Subgroup analysis of continuous variables showed that the effects of children's age, treatment duration and probiotic species on the SCORAD value were not statistically significant.

Conclusion

Evidence on the improvement effect of probiotics on pediatric patients with AD is limited. This study showed that single-strain probiotic treatment exerts a positive effect on AD. Restricted to the quantity and quality of incorporated studies, these conclusions have yet to be validated by high-quality studies.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

益生菌治疗儿童特应性皮炎的疗效:一项系统综述和荟萃分析

背景:特应性皮炎(AD)是儿童常见病。一些研究已经评估了益生菌作为治疗AD的策略。我们的目的是评估益生菌治疗儿童AD的有效性。方法系统检索PubMed/MEDLINE、Embase、Scopus、EBSCO、Web of Science和Cochrane图书馆数据库，以评估2010年1月1日至2023年1月1日期间益生菌治疗与安慰剂组相比对AD患儿SCORAD值影响的随机对照试验(RCTs)。使用Cochrane ROB 2.0评估偏倚风险和证据的确定性。结果共纳入9项随机对照试验的10个结果，涉及1000例患者。其中3个结果作为二分类变量在373例患者中进行分析。另外7组对627例患者进行连续变量分析。二分类变量随机效应模型荟萃分析显示，益生菌组与对照组之间无显著差异[OR = 1.75, 95%可信区间(CI) (0.70, 4.35)， p = 0.23, I2 = 68%]。连续变量随机效应模型的荟萃分析显示，益生菌组与对照组之间存在显著差异[MD = - 4.24, 95% CI (- 7.78， - 0.71)， p = 0.002, I2 = 71%]。连续变量亚组分析显示，患儿年龄、治疗时间和益生菌种类对SCORAD值的影响均无统计学意义。结论益生菌对儿童AD患者的改善作用证据有限。本研究表明，单菌种益生菌处理对AD有积极作用。受纳入研究的数量和质量限制，这些结论尚未得到高质量研究的验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Translational Allergy Immunology and Microbiology-Immunology

CiteScore

7.50

自引率

4.50%

发文量

117

审稿时长

12 weeks

期刊介绍： Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.